Chemotherapy drugs like cisplatin are highly effective cancer treatments, but they can also cause significant damage to the kidneys. New research has uncovered an unexpected way to protect the kidneys from this side effect – using a compound called dichloroacetate (DCA). DCA appears to work by inhibiting two key pathways that lead to cell death in the kidneys, the caspase and mitochondrial apoptosis pathways. This discovery could pave the way for new treatments to prevent cisplatin-induced kidney injury and allow more patients to safely undergo this life-saving cancer therapy.
Protecting the Kidneys from Chemotherapy Damage
Cisplatin is a powerful chemotherapy drug used to treat a wide range of solid tumors, including lung, ovarian, and testicular cancers. However, one of the major downsides of cisplatin is its tendency to cause significant damage to the kidneys, a side effect known as cisplatin-induced nephrotoxicity.
When cisplatin enters the kidneys, it can trigger a cascade of events that leads to the death of the renal tubular cells – the cells responsible for filtering waste and reabsorbing essential nutrients. This cell death, or apoptosis, is driven by the activation of two key pathways: the mitochondrial apoptosis pathway and the death receptor pathway.
Dichloroacetate to the Rescue
A team of researchers led by Hideki Kimura at the University of Fukui in Japan has now uncovered a surprising way to protect the kidneys from this damage – using a compound called dichloroacetate (DCA). DCA is a chemical that has previously been studied for its potential to treat cancer, but the new research suggests it may also have a role in preventing cisplatin-induced kidney injury.
The researchers found that DCA was able to significantly reduce the activation of the caspase-3 and caspase-8 enzymes, which are key players in the mitochondrial and death receptor apoptosis pathways, respectively. DCA accomplished this by:
1. Inhibiting the JNK/14-3-3/Bax/caspase-9 pathway, which is involved in the mitochondrial apoptosis pathway.
2. Increasing the expression of cFLIP, an anti-apoptotic protein that suppresses the activation of caspase-8 in the death receptor pathway.
Interestingly, DCA was able to provide these protective effects without reducing the overall inflammatory response or completely restoring the energy production in the mitochondria – two other factors that contribute to cisplatin-induced kidney damage. This suggests that DCA’s ability to target the specific apoptosis pathways may be the key to its protective action.
Translating to the Clinic
The researchers also tested the effects of DCA in a mouse model of cisplatin-induced acute kidney injury. They found that DCA was able to significantly reduce markers of kidney damage, such as elevated blood creatinine and blood urea nitrogen levels, as well as the degree of tubular cell death and cast formation in the kidneys.
These findings indicate that DCA could be a promising therapeutic candidate for preventing cisplatin-induced nephrotoxicity in cancer patients. By preserving the kidney function, DCA may allow more patients to safely undergo cisplatin treatment and benefit from its anti-cancer effects.
The next step will be to further investigate the precise mechanisms by which DCA exerts its protective effects and to explore the potential for using DCA in combination with cisplatin in clinical trials. If successful, this could represent a significant advancement in the management of cisplatin-induced kidney injury and improve the overall outcomes for cancer patients.
Author credit: This article is based on research by Hideki Kimura, Kazuko Kamiyama, Toru Imamoto, Izumi Takeda, Mamiko Kobayashi, Naoki Takahashi, Kenji Kasuno, Takeshi Sugaya, Masayuki Iwano.
For More Related Articles Click Here
